Physician profile
Sukhdeep Kaur
NPI 1689937740
$323.53
in general payments reported to CMS, 2019-2025
10 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.50 · 2020: $17.25 · 2022: $11.72 · 2023: $90.11 · 2024: $64.87 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $80.75 | 2024-2025 | Cresemba |
| Amgen INC. | $61.49 | 2020-2023 | Blincyto |
| Sanofi-Aventis U.S. LLC | $44.47 | 2025 | |
| Janssen Biotech, INC. | $31.43 | 2023 | Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $26.16 | 2022-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $18.66 | 2024 | |
| Syndax Pharmaceuticals, INC. | $16.46 | 2025 | Niktimvo |
| Taiho Oncology, INC. | $15.99 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $14.62 | 2024 | Sancuso |
| Sobi, INC | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhdeep Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.